Jeffrey Jones
Chief Medical OfficerDr. Jeffrey Jones, also known as Jeff, M.D. M.P.H. M.B.A. serves as Chief Medical Officer at Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) since February 2022. Dr. Jones has clinical development experience in academia and industry with skills ranging from clinical trials, drug development, medical education and healthcare management. Dr. Jones joined Cullinan from Bristol Myers Squibb (BMS) where, he served as Vice President of Global Drug Development, Lymphoma and Myeloid Diseases from April 2020 to February 2022 and also as Executive Medical Director of Global Clinical Research and Development from August 2017 to April 2020. Dr. Jones led the development and lifecycle management strategy for Reblozyl. Dr. Martin brings to Cullinan Oncology of translational medicine and clinical research expertise and is Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline. Dr. Jones joined Celgene Corporation in 2017 as Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development. In that role he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development. Dr. Jones's has successful academic tenure and deep expertise in oncology drug development to create new standards-of-care for patients with cancer. Before joining the industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, a M.P.H. from the University of Texas School of Public Health and a M.D. from the University of Michigan Medical School.
Positions
- Company NameCullinan Therapeutics, Inc.Stock CodeCGEMPositionChief Medical OfficerColleagues
- NANadim AhmedPresident, CEO & Director
- AAAnthony A. RosenbergIndependent Chairman of the Board
- MKMary Kay FentonChief Financial Officer
- PAPatrick A. BaeuerleCo-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
- JMJennifer MichaelsonChief Scientific Officer
- SWStephen W. WebsterIndependent Director
- DDDavid D. MeekIndependent Director
